Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AbbVie, FDA and Parkinson's Disease
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson's disease (PD). The drug will be marketed under the trade name Vyalev.
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
AbbVie says latest FDA approval expands Botox use beyond face
Botox Cosmetic expands beyond face for the first time as FDA approves the anti-wrinkle therapy for treating platysma bands. Read more here.
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.
AbbVie’s Vyalev approved by FDA in advanced Parkinson’s disease
AbbVie announced that the FDA has approved Vyalev as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.
FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment
The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor fluctuations in adults with advanced Parkinson's disease (PD). The chronic neurological disorder is marked by symptoms such as tremors and muscle rigidity,
8h
AbbVie: Strong Dividends But Humira Disappoints
Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...
4d
on MSN
Analysts revise AbbVie stock price target ahead of earnings
Related: Analyst revises AbbVie stock price target on drug-sale estimates Sales eroded, however, as Humira faced competition ...
24/7 Wall St
7d
Dividend Aristocrat AbbVie Just Paid Investors; Here's How Much They Received
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.
Crain's Chicago Business
5d
New AbbVie Parkinson’s drug finally gets green light to hit U.S. market
After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...
1d
AbbVie Gets Accelerated Public Reimbursement Approval Of Epkinly In Nine Canadian Provinces
Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...
Zawya
11h
CRISP Program, a new step by AbbVie to foster scientific expertise in the Middle East and Africa region
AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...
Crain's Chicago Business
8d
AbbVie tries to fast-track new cancer drug for approval to join 2 others in its pipeline
There are no approved therapies to tackle c-Met protein overexpression, AbbVie said in a press release. C-Met is a receptor ...
9h
The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi
Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Vyalev
New York Stock Exchange
Parkinson's disease
United States
Epkinly
Feedback